Medexus Pharmaceuticals reports Q4 results
Jun. 22, 2023 12:48 AM ETMedexus Pharmaceuticals Inc. (MEDXF), MDP:CABy: Meghavi Singh, SA News Editor
- Medexus Pharmaceuticals press release (OTCQX:MEDXF): Q4 adjusted EBITDA of $4.8 million in fiscal Q4 2023, a year-over-year increase of $3.7 million.
- Revenue of $28.6M (+41% Y/Y) in-line.
- Cash and cash equivalents (and total available liquidity) of $13.1 million at March 31, 2023.
Recommended For You
Comments
Have a tip? Submit confidentially to our News team. Found a factual error? Report here.